Skip to content

F1000Research

ISSN 2046-1402

10 papers in the library · 187 citations · publishing 2013-2025

Papers

Over 30 million psychedelic users in the United States

F1000Research March 28, 2013 Teri Suzanne Krebs, Pål-ørjan Johansen 125 citations

In 2010, about 32 million people in the United States had used psychedelics such as LSD, psilocybin, mescaline, or peyote at least once in their lives. Among those aged 21 to 64, 17% reported lifetime use, with 22% of males and 12% of females. The highest rate of use occurred in people aged 30 to 34, where 20% had used psychedelics, including 26% of men and 15% of women. These estimates come from a national survey of 57,873 individuals aged 12 and older.

A physiological examination of perceived incorporation during trance.

F1000Research January 1, 2019 Helané Wahbeh, Cedric Cannard, Jennifer Okonsky et al. 21 citations

In a controlled experiment with 13 healthy adult trance channels, voice recordings showed increased arousal and power differences in specific frequency bins when participants read a story in a channeling state compared to a no-channeling state. However, electroencephalography, electrocardiography, galvanic skin response, and respiration measures did not differ significantly between the two states, despite participants reporting distinct subjective experiences. The findings suggest that while voice parameters may reflect the channeling experience, other physiological measures do not capture it. Future research should explore alternative measures such as EEG connectivity, fMRI, and biomarkers.

A whole genome atlas of 81 Psilocybe genomes as a resource for psilocybin production.

F1000Research September 23, 2021 Kevin Mckernan, Liam T. Kane, Yvonne Helbert et al. 10 citations

The Psilocybe genus produces psychoactive compounds like psilocybin, psilocin, baeocystin, and aeruginascin. The widespread ability to synthesize psilocybin is thought to come from a horizontal gene transfer of a ~20Kb gene cassette. A new high-quality reference genome from long-read sequencing revealed variation in this cassette and enabled shotgun sequencing of spores from many strains. Here, 81 new Psilocybe genomes were assembled and compared to the P. envy reference. Surprisingly, Psilocybe galindoi, Psilocybe tampanensis, and Psilocybe azurescens lack sequence coverage for the known synthesis pathway but show amino acid homology to an alternative pathway, suggesting convergent evolution of psilocybin synthesis.

A draft reference assembly of the Psilocybe cubensis genome

F1000Research June 15, 2021 Kevin Mckernan, Liam T. Kane, Seth Crawford et al. 10 citations

The genome of the psychoactive Psilocybe cubensis mushroom was assembled using high-fidelity single molecule sequencing. The genome is 46.6 megabases in size, has a guanine-cytosine content of 46%, and is arranged in 32 contigs with an N50 of 3.3 megabases. Completeness assessment shows 97.6% of conserved genes are present, with 1.2% duplicated. The psilocybin synthesis cluster is contained within a single 3.2 megabase contig. The genome data are publicly available through NCBI BioProject under accessions PRJNA687911 and PRJNA700437.

Development of a physiologically based pharmacokinetic (PBPK) model of psilocybin and psilocin from magic mushroom in rats and humans

F1000Research March 15, 2021 Prinya Musikaphongsakul, Kimheang Ya, Pakpoom Subsoontorn et al. 6 citations

A physiologically based pharmacokinetic model predicts concentrations of psilocin, the active metabolite of psilocybin, in plasma and brain after intravenous and oral administration in rats and humans. The model, built from three published studies, uses seven organ compartments and shows good overall agreement with observed data, though oral doses are under-predicted and intravenous doses over-predicted. This tool may help design safer dosing regimens for therapeutic use.

Both partners practicing orgasmic meditation report having a mystical-type experience: results using the Mystical Experience Questionnaire

F1000Research July 22, 2021 Vivian Siegel, Benjamin Emmert-Aronson 5 citations

A structured, partnered meditative practice involving manual clitoral stimulation can trigger mystical-type experiences in both participants. In a survey of 780 practitioners recalling a single powerful session, 62% reported a complete mystical experience as measured by the Mystical Experience Questionnaire (MEQ30), with an average total score of 3.35. A separate study of 56 partnered pairs found 23% reported a complete mystical experience, with an average score of 3.21. The experience was strongly correlated between partners, and the role of stroker or strokee also influenced the reported intensity. Whether the brain activity during this practice resembles that of other mystical experiences remains unknown.

Social pain: A systematic review on interventions

F1000Research January 10, 2025 Brandon M. Brooks, Francisco J. Cordero, Stephen L. Alchermes et al. 3 citations

Social pain—emotional distress from harm to social connections, such as exclusion or rejection—can intensify physical pain. This systematic review of 14 randomized controlled trials found that acetaminophen, deceptive and open-label placebos, mindfulness training, and psilocybin reduce social pain. Combining acetaminophen with forgiveness was more effective than either alone. Pharmacological interventions target neural pathways shared by physical and social pain. Both pharmacological and non-pharmacological options are available for reducing social pain.

A draft sequence reference of the Psilocybe cubensis genome

F1000Research April 9, 2021 Kevin Mckernan, Liam T. Kane, Seth Crawford et al. 3 citations

Using high-fidelity single molecule sequencing, the genome of the psychoactive Psilocybe cubensis mushroom was assembled. The genome is 46.6 megabases in size, has a guanine-cytosine content of 46%, and is organized into 32 contigs with an N50 of 3.3 megabases. Completeness assessment shows 97.6% of conserved orthologs are present, with 1.2% duplicated. The psilocybin synthesis cluster is located on a single 3.2 megabase contig. The assembled genome sequence is publicly available through NCBI BioProject under accessions PRJNA687911 and PRJNA700437.

The gamma-band activity model of the near-death experience: a critique and a reinterpretation.

F1000Research January 1, 2024 Nigel A Shaw 2 citations

Near-death experiences (NDEs) are profound mental events occurring near biological death, often explained materialistically as hallucinations. Recent animal and clinical studies report a surge of high-frequency electroencephalogram (EEG) activity, specifically gamma-band activity (GBA), around the time of death, when cortical activity is otherwise low. This perimortem GBA burst has been proposed as the neural basis of NDE. This study examines three questions: whether standard GBA is contaminated by muscle artifacts, whether NDE-mimicking agents also involve GBA, and whether the surge originates subcortically (in the amygdala) and is recorded at the cortex via volume conduction. The authors conclude that while the GBA surge is genuine and intriguing, evidence does not support it as the neurobiological foundation for NDE.

Qualitative analysis of first-person accounts of noetic experiences

F1000Research June 25, 2021 Helané Wahbeh, Nina Fry, Paolo Speirn et al. 2 citations

Noetic experiences—inner wisdom, direct knowing, or intuition—are often kept private due to cultural taboos, despite growing evidence they may be real. An online survey of 521 English-speaking adults worldwide collected demographic data and four open-ended questions about such experiences. Thematic analysis identified five main themes: Ways of Engagement, Ways of Knowing, Types of Information, Ways of Affecting, and Ways of Expressing. Common codes included sharing with others, impacting decision-making, intuition or just knowing, meditation or hypnosis, inner visions, setting intentions, healing others, writing for self, and inner voice. Future research aims to explore these themes and develop standardized evaluation methods to inform curricula and therapies.